Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

(2013) Iwona Hus et al.   FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

(2013) Lisa Christiansson et al.   PLoS One

The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins?

(2013) Sven Brandau et al.   SEMINARS IN CANCER BIOLOGY

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

(2012) Claudia A. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunosuppressive activity of CD14+ HLA-DR− cells in squamous cell carcinoma of the head and neck

(2012) Kazuaki Chikamatsu et al.   CANCER SCIENCE

On the armament and appearances of human myeloid-derived suppressor cells

(2012) Isabel Poschke et al.   CLINICAL IMMUNOLOGY

Interferon alpha for Treatment of Chronic Myeloid Leukemia

(2012) Bengt Simonsson et al.   CURRENT DRUG TARGETS

Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability

(2012) Barry D. Hock et al.   IMMUNOLOGY

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples

(2012) Athanasios Kotsakis et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Myeloid-derived Suppressor Cells in Cancer Patients

(2012) Alberto J. Montero et al.   JOURNAL OF IMMUNOTHERAPY

Unknown

(2012) Karina Zitta et al.   MOLECULAR MEDICINE

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

(2012) Suzanne Ostrand-Rosenberg et al.   SEMINARS IN CANCER BIOLOGY

Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate

(2011) Emmanuel Bachy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

(2011) Kazuma Ohyashiki et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells

(2011) Archana Thakur et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

(2011) Paola Filipazzi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

(2011) James Finke et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation

(2011) R. Rotondo et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

(2011) Melissa G Lechner et al.   Journal of Translational Medicine

First-line therapy for CML: nilotinib comes of age

(2011) Jeff Davies   LANCET ONCOLOGY

S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression

(2011) M. Ichikawa et al.   MOLECULAR CANCER RESEARCH

Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor Cells in the Tumor Microenvironment via Upregulation of MCP-1

(2011) Kimberly C. Boelte et al.   PLoS One

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

(2010) Xiangli Chen et al.   CANCER BIOLOGY & THERAPY

Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive

(2010) Jose M. Rojas et al.   EXPERIMENTAL HEMATOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

(2010) Thomas Condamine et al.   TRENDS IN IMMUNOLOGY

Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer

(2009) P.-Y. Pan et al.   CANCER RESEARCH

IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer

(2009) Rita Rotondo et al.   INTERNATIONAL JOURNAL OF CANCER

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD